3 papers
stat.ME2019
Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Matteo Quartagno, A. Sarah Walker, Abdel G. Babiker +4
Background. Non-inferiority (NI) trials are increasingly used to evaluate new treatments expected to have secondary advantages over standard of care, but similar efficacy on the pr…
stat.ME2019
Adding new experimental arms to randomised clinical trials: impact on error rates
Babak Choodari-Oskooei, Daniel J Bratton, Melissa R Gannon +3
Background: Experimental treatments pass through various stages of development. If a treatment passes through early phase experiments, the investigators may want to assess it in a…
stat.ME2018
Re-thinking non-inferiority: a practical trial design for optimising treatment duration
Matteo Quartagno, A. Sarah Walker, James R. Carpenter +2
Background: trials to identify the minimal effective treatment duration are needed in different therapeutic areas, including bacterial infections, TB and Hepatitis--C. However, sta…